ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care

AstraZeneca to proceed with regulatory filings to convert from conditional to full approval in the US and EU

... | June 5, 2023

Related Keywords

Switzerland ,Cambridge ,Cambridgeshire ,United Kingdom ,Boston ,Massachusetts ,United States ,American ,Pathw Cardiol ,J Vasc Endovasc ,Coll Cardiol ,Stuartj Connolly ,Journal Of The American Society Hematology ,Heart Rhythm Society ,Senior Scientist At Population Health Research Institute ,Astrazeneca ,Mcmaster University ,Alexion Pharmaceuticals Inc ,Company On Twitter Astrazeneca ,Safety Monitoring Board ,Senior Scientist ,Population Health Research Institute ,Executive Vice President ,Prescribing Information ,Rare Diseases ,Andexanet Alfa ,Drugs Ther ,Esp Enferm ,Patients With Atrial Fibrillation ,American College ,American Heart Association Task Force ,Clinical Practice Guidelines ,Heart Rhythm ,American Society ,Atrial Fibrillation ,Novel Methods ,Alexion Pharmaceuticals ,Astrazeneca Plc Stock Exchange ,News ,Information ,Press Release ,O ,Fproceed ,Ith ,Egulatory ,Filings ,Convert ,Rom ,Onditional ,Bull ,Approval ,N ,The ,Us ,Nd Azn Gb0009895292 ,